Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alkermes, Amplyx, Ansun, Ascletis, Axcella, Azurrx, Betagenon/Balticgruppen, Chiasma, Clovis, Enterprise, GNI Group, I-Mab, Merck, Neuroptika, Novavax, Precigen, Syndax, Unity.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Translumina Therapeutics.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cortexyme, Imara, Lupin.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Algernon, Azurrx, Bio-Path, Cerecor, Debiopharm, Gyroscope, Novo Nordisk, Treadwell, Viela.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Azurrx, Blade, Boehringer, Botanix, Eloxx, Epirium, Nektar, Sapience, Vaccibody, VBL.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Angion Biomedica, Arch Biopartners, Bioaegis, Biontech, Cstone, Cytodyn, Eli Lilly, Enlivex, Everest Medicines, Humanigen, Idorsia, Innovent Biologics, Kamada, Ligand, Novavax, Oncolys, Pharming, Shanghai Fosun, Tessa.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Babylon, Beyond Air, Exthera, Neurologica.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adverum, Arcturus, Arrowhead, BMS, Byondis, Catalyst, Destiny, Eisai, Equillium, Fulcrum, Indalo, Kezar, Kymab, Revance, Romark, SAB, Tyme.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Asclepius Meditec, Mir Scientific.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anaptysbio, Avadel, Axsome, BMS, Eli Lilly, Enlivex, Genentech, Humanigen, Innovent, Kamada, Krystal, Logicbio, Ovid, Pharming, Precigen, Rhovac, Seres.